Finding ways to reduce side effects of cancer immunotherapy while keeping it effective
Developing strategies to inhibit cancer immunotherapy-induced immune-related adverse events without impeding anti-tumor immunity
This study is looking at ways to make cancer immunotherapy safer by reducing unwanted side effects that can happen when the immune system gets too active, and it's designed for people who are receiving this type of treatment.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Utah NIH-funded |
| Lab location | 1 site (Salt Lake City, United States) |
| Project ID | NIH-10755293 on NIH RePORTER |
What this research studies
This research investigates how to minimize the harmful side effects caused by cancer immunotherapy, which can sometimes trigger autoimmune reactions in patients. By using special mouse models that are prone to autoimmune diseases, the researchers aim to understand the balance between fighting cancer and avoiding these adverse immune responses. The study will analyze various genetic and cellular factors to identify strategies that enhance anti-tumor immunity while reducing the risk of autoimmune complications.
Who could benefit from this research
Good fit: Ideal candidates for this research are cancer patients who are receiving or considering immunotherapy and may be at risk for immune-related adverse events.
Not a fit: Patients who are not undergoing cancer treatment or those whose cancers do not involve immunotherapy may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to safer cancer immunotherapy treatments with fewer side effects for patients.
How similar studies have performed: Previous research has shown promise in managing immune-related adverse events in cancer therapies, indicating that this approach could build on existing knowledge.
Where this research is happening
Salt Lake City, United States
- University of Utah — Salt Lake City, United States (Active)
Researchers
- Principal investigator: Young, Arabella — University of Utah
- Study coordinator: Young, Arabella
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.